

Nociceptin/orphanin FQ opioid peptide (NOP) receptor and  $\mu$ -opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain

Klaus Schiene, Wolfgang Schröder, Klaus Linz, Stefanie Frosch, Thomas M. Tzschentke, Ulla Jansen, Thomas Christoph



PII: S0014-2999(18)30261-9  
DOI: <https://doi.org/10.1016/j.ejphar.2018.05.005>  
Reference: EJP71787

To appear in: *European Journal of Pharmacology*

Received date: 12 December 2017  
Revised date: 4 May 2018  
Accepted date: 8 May 2018

Cite this article as: Klaus Schiene, Wolfgang Schröder, Klaus Linz, Stefanie Frosch, Thomas M. Tzschentke, Ulla Jansen and Thomas Christoph, Nociceptin/orphanin FQ opioid peptide (NOP) receptor and  $\mu$ -opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.05.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Nociceptin/orphanin FQ opioid peptide (NOP) receptor and  $\mu$ -opioid peptide (MOP)**

**receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of  
arthritic pain**

Klaus Schiene<sup>a\*</sup>, Wolfgang Schröder<sup>b</sup>, Klaus Linz<sup>c</sup>, Stefanie Frosch<sup>c</sup>, Thomas M. Tzschentke<sup>a</sup>,  
Ulla Jansen<sup>a</sup>, Thomas Christoph<sup>a</sup>

<sup>a</sup>Department of Pharmacology, Grünenthal GmbH, Aachen, Germany

<sup>b</sup>Department of Translational Science and Intelligence, Grünenthal GmbH, Aachen, Germany

<sup>c</sup>Department of Preclinical Drug Development, Grünenthal GmbH, Aachen, Germany

\*Corresponding author:

Dr Klaus Schiene, Grünenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Germany.

*Tel:* +49 241 569-2896. *Email:* klaus.schiene@grunenthal.com

Download English Version:

<https://daneshyari.com/en/article/8528959>

Download Persian Version:

<https://daneshyari.com/article/8528959>

[Daneshyari.com](https://daneshyari.com)